p27kip1 functional regulation in human cancer: A potential target for therapeutic designs

B. Belletti, M. S. Nicoloso, M. Schiappacassi, E. Chimienti, S. Berton, F. Lovat, A. Colombatti, G. Baldassarre

Research output: Contribution to journalArticle

Abstract

The mitotic cell cycle is a tightly regulated process that ensures the correct division of one cell into two daughter cells. Progress along the different phases of the cell cycle is positively regulated by the sequential activation of a family of serine-threonine kinases called CDKs (Cyclin Dependent Kinases). Their activity is counteracted by small proteins known as CDK inhibitors (CKI) that ensure the correct timing of CDK activation in the different phases of the cell cycle. The present review will deal with the role of one of this CKI, p27kip1, in human cancer, focusing in particular on the mechanisms underlying its functional inactivation in tumor cells. p27kip1 protein downregulation is usually achieved by proteasomal degradation and is often correlated to a worse prognosis in several types of human cancers, resulting in the reduction of disease free and overall survival. More recently, it has been proposed that p27kip1 protein, rather than degraded, can be functionally inactivated. The mechanisms and the implications of these two types of p27kip1 deregulation will be discussed and some Potential therapeutic approaches targeting p27kip1 functions will be proposed.

Original languageEnglish
Pages (from-to)1589-1605
Number of pages17
JournalCurrent Medicinal Chemistry
Volume12
Issue number14
DOIs
Publication statusPublished - 2005

Fingerprint

Cyclin-Dependent Kinases
Cyclin-Dependent Kinase Inhibitor p27
Cell Cycle
Cells
Neoplasms
Protein-Serine-Threonine Kinases
Chemical activation
Cell Division
Disease-Free Survival
Deregulation
Therapeutics
Down-Regulation
Tumors
Degradation
Proteins

Keywords

  • Adenoviral vectors
  • Cell cycle regulation
  • CKI
  • Gene therapy
  • p27
  • Proteasome degradation
  • Subcellular localization
  • Tumor progression

ASJC Scopus subject areas

  • Organic Chemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

p27kip1 functional regulation in human cancer : A potential target for therapeutic designs. / Belletti, B.; Nicoloso, M. S.; Schiappacassi, M.; Chimienti, E.; Berton, S.; Lovat, F.; Colombatti, A.; Baldassarre, G.

In: Current Medicinal Chemistry, Vol. 12, No. 14, 2005, p. 1589-1605.

Research output: Contribution to journalArticle

Belletti, B, Nicoloso, MS, Schiappacassi, M, Chimienti, E, Berton, S, Lovat, F, Colombatti, A & Baldassarre, G 2005, 'p27kip1 functional regulation in human cancer: A potential target for therapeutic designs', Current Medicinal Chemistry, vol. 12, no. 14, pp. 1589-1605. https://doi.org/10.2174/0929867054367149
Belletti, B. ; Nicoloso, M. S. ; Schiappacassi, M. ; Chimienti, E. ; Berton, S. ; Lovat, F. ; Colombatti, A. ; Baldassarre, G. / p27kip1 functional regulation in human cancer : A potential target for therapeutic designs. In: Current Medicinal Chemistry. 2005 ; Vol. 12, No. 14. pp. 1589-1605.
@article{97b2942644e74fbc97c6268b83c8a9e0,
title = "p27kip1 functional regulation in human cancer: A potential target for therapeutic designs",
abstract = "The mitotic cell cycle is a tightly regulated process that ensures the correct division of one cell into two daughter cells. Progress along the different phases of the cell cycle is positively regulated by the sequential activation of a family of serine-threonine kinases called CDKs (Cyclin Dependent Kinases). Their activity is counteracted by small proteins known as CDK inhibitors (CKI) that ensure the correct timing of CDK activation in the different phases of the cell cycle. The present review will deal with the role of one of this CKI, p27kip1, in human cancer, focusing in particular on the mechanisms underlying its functional inactivation in tumor cells. p27kip1 protein downregulation is usually achieved by proteasomal degradation and is often correlated to a worse prognosis in several types of human cancers, resulting in the reduction of disease free and overall survival. More recently, it has been proposed that p27kip1 protein, rather than degraded, can be functionally inactivated. The mechanisms and the implications of these two types of p27kip1 deregulation will be discussed and some Potential therapeutic approaches targeting p27kip1 functions will be proposed.",
keywords = "Adenoviral vectors, Cell cycle regulation, CKI, Gene therapy, p27, Proteasome degradation, Subcellular localization, Tumor progression",
author = "B. Belletti and Nicoloso, {M. S.} and M. Schiappacassi and E. Chimienti and S. Berton and F. Lovat and A. Colombatti and G. Baldassarre",
year = "2005",
doi = "10.2174/0929867054367149",
language = "English",
volume = "12",
pages = "1589--1605",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "14",

}

TY - JOUR

T1 - p27kip1 functional regulation in human cancer

T2 - A potential target for therapeutic designs

AU - Belletti, B.

AU - Nicoloso, M. S.

AU - Schiappacassi, M.

AU - Chimienti, E.

AU - Berton, S.

AU - Lovat, F.

AU - Colombatti, A.

AU - Baldassarre, G.

PY - 2005

Y1 - 2005

N2 - The mitotic cell cycle is a tightly regulated process that ensures the correct division of one cell into two daughter cells. Progress along the different phases of the cell cycle is positively regulated by the sequential activation of a family of serine-threonine kinases called CDKs (Cyclin Dependent Kinases). Their activity is counteracted by small proteins known as CDK inhibitors (CKI) that ensure the correct timing of CDK activation in the different phases of the cell cycle. The present review will deal with the role of one of this CKI, p27kip1, in human cancer, focusing in particular on the mechanisms underlying its functional inactivation in tumor cells. p27kip1 protein downregulation is usually achieved by proteasomal degradation and is often correlated to a worse prognosis in several types of human cancers, resulting in the reduction of disease free and overall survival. More recently, it has been proposed that p27kip1 protein, rather than degraded, can be functionally inactivated. The mechanisms and the implications of these two types of p27kip1 deregulation will be discussed and some Potential therapeutic approaches targeting p27kip1 functions will be proposed.

AB - The mitotic cell cycle is a tightly regulated process that ensures the correct division of one cell into two daughter cells. Progress along the different phases of the cell cycle is positively regulated by the sequential activation of a family of serine-threonine kinases called CDKs (Cyclin Dependent Kinases). Their activity is counteracted by small proteins known as CDK inhibitors (CKI) that ensure the correct timing of CDK activation in the different phases of the cell cycle. The present review will deal with the role of one of this CKI, p27kip1, in human cancer, focusing in particular on the mechanisms underlying its functional inactivation in tumor cells. p27kip1 protein downregulation is usually achieved by proteasomal degradation and is often correlated to a worse prognosis in several types of human cancers, resulting in the reduction of disease free and overall survival. More recently, it has been proposed that p27kip1 protein, rather than degraded, can be functionally inactivated. The mechanisms and the implications of these two types of p27kip1 deregulation will be discussed and some Potential therapeutic approaches targeting p27kip1 functions will be proposed.

KW - Adenoviral vectors

KW - Cell cycle regulation

KW - CKI

KW - Gene therapy

KW - p27

KW - Proteasome degradation

KW - Subcellular localization

KW - Tumor progression

UR - http://www.scopus.com/inward/record.url?scp=21244446670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244446670&partnerID=8YFLogxK

U2 - 10.2174/0929867054367149

DO - 10.2174/0929867054367149

M3 - Article

C2 - 16022660

AN - SCOPUS:21244446670

VL - 12

SP - 1589

EP - 1605

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 14

ER -